Dose response and safety of the daily, oral RIG-I agonist...

Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial

Yuen, M.-F., Elkashab, M., Chen, C.-Y., Coffin, C., Fung, S., Greenbloom, S., Jang, J.W., Jeng, R.W.-J., Kim, D.J., Kim, Y.J., Kim, W., Lee, K.S., Lim, Y.-S., Ramji, A., Iyer, R., Macfarlane, C., Jack
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
68
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(18)31267-4
Date:
April, 2018
File:
PDF, 134 KB
english, 2018
Conversion to is in progress
Conversion to is failed